Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2021-12-24 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力公司章程（2021年12月修订）
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Company Articles of Association" or "Company Bylaws." It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, share issuance, shareholder meetings, voting procedures, and other governance-related rules. It references relevant laws such as the Company Law and Securities Law of China. The content is focused on the internal rules and governance framework of the company rather than financial performance, audit results, or announcements. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. Instead, it is a governance document outlining the company's internal rules and procedures. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance document, not just an announcement or summary.
2021-12-24 Chinese
天士力关于拟变更注册资本暨修改《公司章程》相关条款的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from the board of directors of TianShiLi Pharmaceutical Group Co., Ltd. regarding a proposed change in registered capital and corresponding amendments to the company's articles of association. It details the reduction of registered capital due to cancellation of repurchased shares and the related changes to the company's share capital figures. The document is a formal announcement of a corporate action requiring shareholder approval, not a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The content fits the category of Share Issue/Capital Change announcements, as it concerns changes in share capital and company registration details.
2021-12-24 Chinese
天士力独立董事关于公司第八届董事会第8次会议相关事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent director's opinion on a board meeting resolution regarding the adjustment of the use of repurchased shares and their cancellation. It references compliance with laws and regulations and confirms the legality and appropriateness of the share repurchase and cancellation. This is not a full financial report, earnings release, or annual report, but rather a formal opinion related to a share repurchase and capital reduction. The content aligns with a Transaction in Own Shares (POS) filing, which reports on the company's buyback or cancellation of its own shares.
2021-12-24 Chinese
天士力关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders (临时股东大会) for the company TianShiLi Pharmaceutical Group Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholder meeting. The document length is 2720 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2021-12-24 Chinese
天士力关于调整回购股份用途的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from a company regarding the adjustment of the purpose of repurchased shares and their cancellation to reduce registered capital. It details the board meeting decisions, the history of the share repurchase, the reasons for the adjustment, the impact on share capital structure, and includes independent directors' opinions. The document is not a financial report, earnings release, or management discussion but a formal announcement about share repurchase usage and cancellation. This fits the category of Transaction in Own Shares (POS), which covers company announcements about share buybacks or share cancellations.
2021-12-24 Chinese
天士力关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary obtaining a drug registration certificate from the national drug regulatory authority. It details the drug's registration, development, market situation, and potential impact on the company. The document is relatively short (1555 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it is not about publishing a report but about a regulatory milestone. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2021-12-20 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.